Howard H. Yang, Ph.D.

Staff Scientist

Biography

Dr. Howard Yang joined NCI in 2001 as a staff scientist working in bioinformatics, biostatistics, and machine learning in collaborations with different labs in the NCI Center for Cancer Research and the NCI Division of Cancer Epidemiology and Genetics. Before his time at NCI, Dr. Yang has held positions that include: research fellow in the Department of Computer Science and Computer Engineering at La Trobe University and the Department of Electrical and Electronic Engineering at The University of Melbourne, Australia; a frontier researcher in brain science research in the Lab for Information Representation (Amari Lab) and the Institute of Physical and Chemical Research (RIKEN) in Japan; and assistant professor in the Department of Computer Science and Engineering at the Oregon Graduate Institute of Science and Technology (now part of Oregon Health & Science University). Dr. Yang received his doctorate in probability and statistics from Zhongshan (Sun Yat-Sen) University in China. In his more than 30 years of scientific research, he has been working in neural networks, machine learning, signal processing, biostatistics, genomics, and their applications in cancer research, and has published 64 journal papers and 6 articles in books.

Projects

  • NCI Center for Cancer Research (CCR) collaborations

Publications

  • Hu, N., Kadota, M., Liu, H., Abnet, C.C., Su, H., Wu, H., Freedman, N.D., Yang, H.H., Wang, C., Yan, C., Wang, L., Gere, S.,  Hutchinson, S.,  Song, G., Wang, G., Ding, T., Qiao, Y. , Koshiol, J., Dawsey, S.M., Giffen, C., Goldstein, A.M., Taylor, P.R., and Lee, M.P. Genomic landscape of somatic alterations in esophageal squamous cell carcinoma and gastric cancer. Cancer Research, 76(7) (2016): 1714-23.
  • Farhoud, Faraji F., Hu, Y., Yang, H.H., Lee, M.P., Winkler, G.S., Hafner, M., Hunter, K.W.. Post-transcriptional control of tumor cell autonomous metastatic potential by CCR4-NOT deadenylase CNOT7. PLOS Genetics, Jan 25;12(1), 2016.
  • Bai, L., Yang, H.H., Hu, Y., Shukla, A., Ha, N.H., Doran, A., Faraji, F., Goldberger, N., Lee, M.P., Keane, T., Hunter, K.W. An Integrated Genome-Wide Systems Genetics Screen for Breast Cancer Metastasis Susceptibility Genes.  PLoS Genet. 12(4) (2016).
  • Murphy, J., Sherman, M.E., Brown, E.P., Caballero, A.I., Punska, E.C., Pfeiffer, R.M., Yang, H.P., Lee, M.P., Yang, H.H., Gierach, G.L., and Arcaro, K.F. Potential of breastmilk analysis to inform early events in breast carcinogenesis: rationale and considerations. Breast Cancer Res Treat 157:1322 (2016).
  • Aprelikova, O., Chen, K., Touny, L.H.E., Brignatz-Guittard, C., Han, J., Qiu, T., Yang, H.H., Lee, M.P., Zhu, M., and Green, J.E. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis. Clinical Epigenetics 8:38 (2016).
  • Yang, Y., Yang, H.H., Hu, Y., Watson, P.H., Liu, H., Geiger, T.R., Anver, M.R., Haines, D.C., Martin, P., Green, J.E., Lee, M.P., Hunter, K.W., Wakefield, L.M. Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis. Oncotarget. 9;8(19) (2017).
  • Tayyari, F., Gowda, G., Olopade, O., Berg, R., Yang, H.H., Lee, M.P., Ngwa, W., Mittal, S., Raftery, D., and Mohammed, S.I.. Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences. Oncotarget. 9(14) (2018): 11677-11690.